Regen Biopharma declares Series A stock dividend

Regen Biopharma, Inc. announced a special stock dividend in the form of its authorized but unissued Series A Preferred Stock.

Rhea-AI Filing Summary

Regen Biopharma, Inc. announced a special stock dividend in the form of its authorized but unissued Series A Preferred Stock. Shareholders of record on February 3, 2026 are scheduled to receive the dividend on or about February 9, 2026.

Each eligible holder will receive one share of Series A Preferred Stock for every one share of Regen Biopharma common stock, Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock owned as of the record date. The dividend is paid entirely in shares, not cash, and applies across these listed classes of the company’s stock.

Insights

Equity capital structure analyst

Regen grants a one-for-one Series A preferred stock dividend.

Regen Biopharma, Inc. is issuing a stock dividend using its authorized but unissued Series A Preferred Stock. Every share of common stock and the specified preferred series outstanding on February 3, 2026 earns one Series A Preferred share, with distribution expected on or about February 9, 2026. This broad-based grant means all existing holders of the listed classes receive additional equity.

Because the dividend is paid in stock rather than cash, it changes the mix and volume of the company’s outstanding equity without directly affecting cash balances. The impact for investors will depend on the rights and preferences attached to the Series A Preferred Stock, which are not detailed in this excerpt and would be defined in the company’s governing documents.

The timing and mechanics are clearly anchored to the record date and payment date, so ownership as of February 3, 2026 determines who participates. Subsequent company disclosures and governing documents can clarify how Series A Preferred rights, such as voting or conversion features if any, interact with existing securities.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Regen Biopharma (RGBP) announce in this 8-K filing?

Regen Biopharma, Inc. disclosed that its board declared a stock dividend payable in shares of its authorized but unissued Series A Preferred Stock to existing shareholders of several stock classes.

What is the record date for Regen Biopharma's Series A Preferred Stock dividend?

The record date for the stock dividend is February 3, 2026. Shareholders who own eligible Regen Biopharma shares on that date will be entitled to receive the dividend.

When will Regen Biopharma pay the Series A Preferred Stock dividend?

Regen Biopharma plans to pay the stock dividend on or about February 9, 2026 to all shareholders of record as of February 3, 2026.

What is the distribution ratio for Regen Biopharma's Series A Preferred Stock dividend?

Each eligible holder will receive one share of Series A Preferred Stock for every one share of Regen Biopharma common stock, Series A Preferred, Series AA Preferred, Series M Preferred, and Series NC Preferred owned on the record date.

Which Regen Biopharma securities qualify for the Series A Preferred Stock dividend?

The dividend applies to holders of common stock, Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock held as of the February 3, 2026 record date.

Is Regen Biopharma's announced dividend a cash dividend or a stock dividend?

It is a stock dividend, payable in shares of Regen Biopharma’s authorized but unissued Series A Preferred Stock, rather than a cash payment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 06:01 AM Learn about SEC filing dates

false 0001589150 0001589150 2026-01-19 2026-01-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 19, 2026

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada		45-5192997
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Commission File No. 333-191725

8697 La Mesa Blvd, Suite C#107

La Mesa CA 91942

(Address of Principal Executive Offices)

(619) 722 5505

(Issuer’s telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 19, 2026 the Board of Directors of Regen Biopharma, Inc.(“Regen”) declared a dividend to all shareholders of record as of February 3, 2026 (“Record Date”) to be paid to shareholders on or about February 9, 2026 such dividend to be payable in shares of the Regen’s authorized but unissued Series A Preferred Stock and to consist of one share of Series A Preferred Stock for every one share of Regen Biopharma, Inc. Common Stock owned as of the Record Date, every one share of Regen Biopharma, Inc. Series A Preferred Stock owned as of the Record Date, every one share of Series AA Preferred Stock owned as of the Record Date, every one share of Series M Preferred Stock owned as of the Record Date and every one share of Series NC Preferred Stock owned as of the Record Date.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REGEN BIOPHARMA, INC.
Dated: January 21, 2026	By:	/s/ David Koos